Fundraising Fox
Iantrek
Elkins Park, US · Founded 2019 · Delaware corporation · 82 employees on LinkedIn · 7 known investors
Find your way into Iantrek
365 people in our graph can introduce you to the Iantrek team.
Sign up to see every warm intro you have to Iantrek
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Iantrek team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Iantrek develops micro-interventional ophthalmic surgical technologies focused on enhancing total outflow through the uveoscleral pathway to treat glaucoma. Its commercialized bio-interventional solutions are used by surgeons in glaucoma patient care.
Founders & leadership
Iantrek was founded in 2019 by Tsontcho Ianchulev and Sean Ianchulev.
Board
Investors · 7
How we know: the company's own site · aMoon's portfolio page · a partner's Signal profile · funding news · Not right? Tell us
How we know: the company's own site · funding news · Not right? Tell us
How we know: the company's own site · board seat on SEC Form D · Not right? Tell us
How we know: Civilization Ventures Management, Llc's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: JSD Capital, LLC's portfolio page · Not right? Tell us
How we know: US Venture Partners's portfolio page · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$58.2M disclosed across 4 rounds · 2020–2025
▶$34.7MraisedAug 2025 · 21 investors · BiotechnologyRule 506(b)
- Tsontcho IanchulevExecutive Officer, Director
- Todd SoneDirector
- James MazzoDirector
- Adam SzaronosExecutive Officer, Director
- Casey TanseyDirector
- Robert WeinrebDirector
- Marc-Andre MarcotteDirector
- Jeffry K. WeinhuffDirector
- Michael HaydinExecutive Officer
- Farrell TysonDirector
- Offering amount
- $42M
- Amount sold
- $34.7M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.8MraisedFeb 2025 · 4 investors · BiotechnologyRule 506(b)
- Michael HaydinExecutive Officer
- Robert WeinrebDirector
- Tsontcho IanchulevExecutive Officer, Director
- Marc-Andre MarcotteDirector
- Jeffry K WeinhuffDirector
- Farrell TysonDirector
- James MazzoDirector
- Offering amount
- $5.5M
- Amount sold
- $2.8M
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.4MraisedAug 2022 · 25 investors · BiotechnologyRule 506(b)
- Michael George Haydin, IVExecutive Officer
- James MazzoDirector
- Jeffrey K. WeinhuffDirector
- Farrell TysonDirector
- Tsontcho IanchulevExecutive Officer, Director
- Marc-Andre MarcotteDirector
- Robert WeinrebDirector
- Offering amount
- $25M
- Amount sold
- $15.4M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$5.2MraisedOct 2020 · 29 investors · BiotechnologyRule 506(b)
- Robert WeinrebDirector
- James MazzoDirector
- Jeffry K WeinhuffDirector
- Andrew CorleyDirector
- Tsontcho IanchulevExecutive Officer, Director
- Stephen BlochDirector
- Michael HaydinExecutive Officer
- Offering amount
- $5.2M
- Amount sold
- $5.2M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Iantrek went on to found or lead other companies.
Related companies · 1
Companies working in the same space as Iantrek.
In the news
Frequently asked questions
- What does Iantrek do?
- Iantrek develops micro-interventional ophthalmic surgical technologies focused on enhancing total outflow through the uveoscleral pathway to treat glaucoma. Its commercialized bio-interventional solutions are used by surgeons in glaucoma patient care.
- Who founded Iantrek?
- Iantrek was founded by Tsontcho Ianchulev, Sean Ianchulev in 2019.
- Who are Iantrek's investors?
- Iantrek's investors include aMoon, Visionary Ventures, Canaan Partners, Civilization Ventures Management, Llc, FemHealth Ventures, JSD Capital, LLC, US Venture Partners.
- How much funding has Iantrek raised?
- Iantrek has disclosed $58.2M raised across 4 rounds.
- Where is Iantrek headquartered?
- Iantrek is headquartered in Elkins Park, US.